These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
4. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Berenson JR; Ma HM; Vescio R Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821 [TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. Salem K; Brown CO; Schibler J; Goel A Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726 [TBL] [Abstract][Full Text] [Related]
6. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312 [TBL] [Abstract][Full Text] [Related]
7. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350 [TBL] [Abstract][Full Text] [Related]
8. The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance. Meinel FG; Mandl-Weber S; Baumann P; Leban J; Schmidmaier R Mol Cancer Ther; 2010 Feb; 9(2):300-10. PubMed ID: 20124446 [TBL] [Abstract][Full Text] [Related]
9. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Yang M; Huang J; Pan HZ; Jin J Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856 [TBL] [Abstract][Full Text] [Related]
10. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265 [TBL] [Abstract][Full Text] [Related]
11. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma. Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537 [TBL] [Abstract][Full Text] [Related]
12. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Sung B; Kunnumakkara AB; Sethi G; Anand P; Guha S; Aggarwal BB Mol Cancer Ther; 2009 Apr; 8(4):959-70. PubMed ID: 19372569 [TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. Park J; Bae EK; Lee C; Choi JH; Jung WJ; Ahn KS; Yoon SS BMB Rep; 2014 May; 47(5):274-9. PubMed ID: 24286313 [TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009 [TBL] [Abstract][Full Text] [Related]
17. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. Juvekar A; Manna S; Ramaswami S; Chang TP; Vu HY; Ghosh CC; Celiker MY; Vancurova I Mol Cancer Res; 2011 Feb; 9(2):183-94. PubMed ID: 21224428 [TBL] [Abstract][Full Text] [Related]
18. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. Siveen KS; Mustafa N; Li F; Kannaiyan R; Ahn KS; Kumar AP; Chng WJ; Sethi G Oncotarget; 2014 Feb; 5(3):634-48. PubMed ID: 24504138 [TBL] [Abstract][Full Text] [Related]
19. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner. Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669 [TBL] [Abstract][Full Text] [Related]
20. Effect of noncompetitive proteasome inhibition on bortezomib resistance. Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]